Entities

Greta Neffling is publicly named by Business Finland as coordinator and coauthor of the September 2026 Generative AI campaign retrospective. The campaign ended in June 2026; her source-qualified affiliation is recorded without inventing a successor-program role, personal investment or broader employment history.

Timo Sorsa is a Business Finland Head of Program and former Generative AI campaign head. His September 2026 retrospective states that the campaign ran from May 2024 to June 2026. Earlier official work describes data-economy ecosystems and AI applications. The ended campaign is not represented as currently operating, and future program plans are not assumed to be launched.

Tarja Enala is the Business Finland program director who led Health 360 Finland and authored its September 29, 2026 retrospective. The program supported health-sector research, international collaboration and digital and AI applications. Her own retrospective states that Health 360 ended in June 2026. This historical program is not presented as currently active; the publication establishes her program-director affiliation but not a new successor-program appointment.

Sini Uuttu is the publicly named project-manager contact for climate-neutral economy and renewable energy; the issuer’s December 2025 announcement also names her as project director. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Ulf-Erik Widd is the publicly named expert contact for smart machines and shipping. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Joonas Halla is the publicly named Work in Finland business-development manager contact. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Heli Saari is the publicly named Visit Finland area-manager contact. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Karin Wikman is the publicly named expert contact for leading-company innovation projects, research and development and associated ecosystems. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Susanna Lehto is the publicly named marketing coordinator and named contact for Business Finland media assets; own issuer portrait credits also identify her as photographer. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Salla Salovaara is the publicly named Business Finland and Invest in Finland communications contact; the Finnish current media page specifies International PR and Media, while the English media page uses a broader communications title. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Heli Hemgård is the publicly named shared Business Finland, Visit Finland and Work in Finland communications contact. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Maria Arruda is the publicly named Business Finland communications contact. The current own media directory establishes this functional affiliation. Visit Finland, Work in Finland, Invest in Finland and shared group services are qualified as programs or services; this listing does not independently establish legal employment by the Innovation Funding Agency. Appointment dates and additional career details are not disclosed by this source.

Maria Wasastjerna is member of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as CEO of Kvanted in Business Finland’s directory and Managing Partner in Kvanted’s current own directory. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation. Kvanted’s current primary biography identifies her as Managing Partner, with over 15 years of business-law experience in technology, mergers and acquisitions and digital markets. Her PhD concerned the data economy, and her investment focus includes industrial digital and data-driven innovation.

Outi Vaarala is member of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as Executive Vice President at Orion. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation. Orion’s current profile identifies her as Executive Vice President, Research & Development, with earlier oncology and translational-research leadership at Orion, AstraZeneca and MedImmune. She is a professor in pediatric immunology and autoimmune diseases and holds a medical doctorate. Orion independently confirms her Business Finland board membership from 2026.

Sean Salji was introduced by Citadel as Head of Surveyor Capital in Europe in its April 24, 2019 Citadel Conversations interview. He discussed developing investment teams and the resources available within the business. This is an explicitly historical published affiliation; a current Surveyor appointment, subsequent transition date and individual portrait are not established by that source.

Jarno Syrjälä is member of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as Under-Secretary of State at the Ministry for Foreign Affairs. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation.

Justin Lubell currently leads Citadel Global Equities, according to Citadel’s current leadership biography. The same biography records that he joined Citadel in 2020 as a senior managing director at Surveyor Capital and subsequently moved to lead the other equities unit. His Surveyor role is historical. Previously he spent more than a decade as a portfolio manager at Point72, worked in equity derivatives strategy at Bear Stearns and studied economics and political science at the University of Pennsylvania.

Juuso Heinilä is member of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as CEO of Finnvera. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation. Finnvera’s official appointment announcement identifies him as CEO from June 1, 2024, following responsibility for its SME financing.

Yi Zhou is named a Surveyor Capital healthcare portfolio manager in the 2022 leading women in hedge funds profile republished by Citadel. The published biography describes a background in healthcare investing and research, earlier work at JPMorgan and SAC, and economics and mathematics studies at MIT. Her Surveyor affiliation is recorded as published in 2022; a subsequent current role and exact transition dates are not independently verified.

Micah Nance is profiled as a Surveyor Capital technology and media portfolio manager and Citadel partner in a January 2025 interview published as an authorized reprint on Citadel’s website. The profile reports that he joined Citadel in 2012 and became a partner in 2023, working with a Dallas team. Before Citadel he worked in Morgan Stanley equity research and studied at Texas A&M. His role is qualified to the publication date rather than an independently verified October 2026 appointment.

Paula Eerola is member of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as Director General of the Research Council of Finland. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation. The Research Council of Finland’s own leadership directory independently identifies her as Director General responsible for the agency’s administration.

Mackenzie Snyder is named Head of Business Development at Surveyor Capital in Citadel’s own 2026 congratulatory post, preserved as an embedded company post in a public repost. The award organizer independently identifies her Surveyor Capital, Citadel affiliation among its 2026 hedge fund rising stars. Her own LinkedIn identifies Citadel and Williams College. The exact appointment day and an authentic individually named portrait have not been verified.

Tiina Korhonen is vice chair of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as Head of Department at the Ministry of Economic Affairs and Employment. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation.

Phillip Lee leads Surveyor Capital, a Citadel fundamental equities unit, and serves on Citadel’s Portfolio Committee. Citadel’s current biography says he joined Surveyor in 2013 as a senior TMT analyst, became a portfolio manager in 2015 and later served as U.S. deputy head and senior mentor before becoming head in 2021. Previously he worked in Morgan Stanley technology investment banking and at Cadian Capital. He holds an economics BA from Dartmouth and an MBA from Stanford.

Teppo Rantanen is chair of Business Finland’s Governance Board for the appointed term March 23, 2026 to March 22, 2028. The current agency directory identifies the external affiliation as Executive Director at the City of Tampere. The board governs the agency and the Business Finland group and makes funding decisions within government budget authorizations. Board affiliation is not a personal financial participation.

Teija Lahti-Nuuttila leads the Director General’s Office at Business Finland. Earlier event materials describe customer and network responsibilities, while the current leadership directory identifies the Director General’s Office role. This is the publicly listed Business Finland group leadership affiliation. The grant agency and Business Finland Oy are legally separate; a current individual legal employment contract is not established by the shared directory. No personal investment is inferred.

Heidi Elvilä leads talent, legal and administration at Business Finland. Agency documents identify her historic agency personnel responsibilities; the current organization directory publishes the broader shared leadership role. This is the publicly listed Business Finland group leadership affiliation. The grant agency and Business Finland Oy are legally separate; a current individual legal employment contract is not established by the shared directory. No personal investment is inferred.

Hannu Kemppainen leads insight and finance at Business Finland. His earlier published work as strategy director concerns innovation-driven growth and export competitiveness; that earlier title is not substituted for the current leadership directory. This is the publicly listed Business Finland group leadership affiliation. The grant agency and Business Finland Oy are legally separate; a current individual legal employment contract is not established by the shared directory. No personal investment is inferred.

Jenni Santalo leads marketing, communications and digital solutions at Business Finland. She joined its leadership in May 2024 after serving as VTT’s marketing and communications director; the agency’s appointment announcement describes experience in marketing, digital growth and customer experience. This is the publicly listed Business Finland group leadership affiliation. The grant agency and Business Finland Oy are legally separate; a current individual legal employment contract is not established by the shared directory. No personal investment is inferred.

Risto Vuohelainen leads the growth-services area of Business Finland. His published work discusses innovation, commercialization and international growth. His prior internationalization-services title is historical. This is the publicly listed Business Finland group leadership affiliation. The grant agency and Business Finland Oy are legally separate; a current individual legal employment contract is not established by the shared directory. No personal investment is inferred.

Timo Metsä-Tokila leads Business Finland’s funding services. His current public commentary concerns research and development funding and the application and funding-decision process. This is the publicly listed Business Finland group leadership affiliation. The grant agency and Business Finland Oy are legally separate; a current individual legal employment contract is not established by the shared directory. No personal investment is inferred.

Lassi Noponen is Director General of the Innovation Funding Agency Business Finland. The Finnish Government appointed him for a five-year term beginning September 1, 2024. His current responsibilities include leading the public innovation funding and growth organization. The official appointment describes qualifications in law and a Master of Science. His role concerns institutional funding decisions and policy execution, not personal investments.

Business Finland is Finland’s public innovation funding and growth organization. This profile represents the Innovation Funding Agency Business Finland (Innovaatiorahoituskeskus Business Finland), business ID 0512696-4, a government agency under the Ministry of Economic Affairs and Employment. It is recorded as a Company because the available organization model does not have a government-agency type; it is not a private venture firm. The Business Finland brand began in 2018, with the funding agency continuing Tekes’s innovation-funding functions. The agency and the distinct state-owned service company Business Finland Oy, business ID 2725690-3, operate under shared Business Finland leadership. Their legal identities and employment relationships must not be conflated. Its public funding instruments include research and development grants and loans and research commercialization support. Its relevant technology areas include artificial intelligence, quantum computing, industrial deep technology and health innovation. Generative AI and Health 360 Finland ran as programs and ended in June 2026; continuing innovation funding services do not imply that these programs remain active. The 2026–2030 strategy and organization came into force in January 2026, and international export-promotion functions transferred to the Ministry for Foreign Affairs at the end of 2025. Business Finland Venture Capital Ltd was integrated into Tesi in March 2025 and is not the grant agency represented here. The current shared organization publishes seven leaders and an agency governance board appointed for March 23, 2026 to March 22, 2028. Public program and media contacts are separately qualified, rather than presumed to be agency employees. A primary issuer-quoted December 2019 announcement identifies a EUR250,000 Business Finland grant to neuroscience-device company Sooma, separate from its EUR1 million equity financing. Government appropriations, program targets and grant awards are not private fund closes; award dates do not by themselves establish recipient cash disbursement dates. Its open funding database distinguishes funding granted from funding paid. Headquarters are at Porkkalankatu 1 in Helsinki.

Chief Technology Officer at Clarified Precision Medicine, which combines machine-learning analysis with medical expert review for personalized oncology treatment guidance.

Published co-founder of Clarified Precision Medicine; current operating role is unverified.

Co-founder of Clarified Precision Medicine, published as Scientific Advisor in its April2024 financing announcement; own current directory retains the cofounder affiliation.

Chief Executive Officer at Clarified Precision Medicine, which combines machine-learning analysis with medical expert review for personalized oncology treatment guidance.

Board Member at Clarified Precision Medicine, which combines machine-learning analysis with medical expert review for personalized oncology treatment guidance.

Clarified Precision Medicine combines an AI and machine-learning platform with a medical group to help oncologists interpret genomic test results and select personalized cancer treatments. Its asynchronous molecular tumor board provides expert-reviewed, guideline-based therapy options from a patient’s tumor profile. ClarifiedSelect supports treatment guidance; OncoGuardian provides pharmacogenomics and gene-to-drug risk guidance; ClarifiedData supports oncology data analysis and discovery. The company also helps institutions build and sustain their own precision medicine tumor boards. It serves oncology providers, payers, testing laboratories and life-science organizations, with medical experts reviewing recommendations before they are used in clinical workflows.

Co-Founder and Medical Director at Clarified Precision Medicine, which combines machine-learning analysis with medical expert review for personalized oncology treatment guidance.

Co-Founder at Clarified Precision Medicine, which combines machine-learning analysis with medical expert review for personalized oncology treatment guidance.

Jeff Albers is listed by Atlas Venture as venture partner. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Jernej Godec is listed by Atlas Venture as venture partner. The same directory identifies an outside portfolio role: Chief Executive Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Josh Powers is listed by Atlas Venture as finance manager. Published educational qualifications include BS, magna cum laude, Endicott College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Linda C. Bain is listed by Atlas Venture as venture partner. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Alex Harding is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Executive Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Andre Turenne is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer, Matchpoint Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Michael Gladstone is listed by Atlas Venture as partner. Published educational qualifications include AB, magna cum laude, Harvard College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Pascal Fortin is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: President and Chief Scientific Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Ram Aiyar is listed by Atlas Venture as atlas advisor. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Sean Burns is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Scientific Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Angela Lam is listed by Atlas Venture as executive assistant. Published educational qualifications include BA, University of New Hampshire. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Essra Ridha is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: President and Chief Medical Officer, Spolia Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

John Quisel is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: President & Chief Executive Officer, Disc Medicine. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Lainey Rabinow is listed by Atlas Venture as executive assistant. Published educational qualifications include BA, University of Massachusetts Amherst. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Nick Keen is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Founder & Chief Scientific Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Andrea DiMella is listed by Atlas Venture as senior vice president, head of talent. Published educational qualifications include BA, University of California at Santa Cruz. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Kyle Shuckerow is listed by Atlas Venture as finance manager. Published educational qualifications include BS, University of Connecticut. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Ommer Chohan is listed by Atlas Venture as chief financial officer. Published educational qualifications include Master of Legal Studies, Washington University in St. Louis MBA, Johnson School at Cornell University BA, University of Toronto. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Steven Sweeney is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Executive Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Deep33 is a venture capital firm investing in the infrastructure needed to scale artificial intelligence: quantum computing and post-quantum security, advanced energy and grid systems, AI chips and computing infrastructure, and robotics and autonomous manufacturing. It backs companies from seed through Series B after scientific risk has been reduced, with a focus on the U.S.–Israel technology corridor. Its operating programs help founders pursue non-dilutive funding and reach government, industrial and technology customers.

Former CEO of Tesla Israel, Israeli Navy Naval Academy graduate and combat officer, seasoned technology leader and entrepreneur

Strategy and ecosystem leader with 10+ years across innovation and deep tech; Ex-Deloitte Catalyst, 8200 Alumni Association, critical minerals thought leader

CEO of Hut 8 Corp. (NASDAQ, TSX: HUT)

Former Commander of Israel’s elite Talpiot Program (ret.Col); MSc in Quantum Optics; Global Quantum Ecosystem Advisor

Judith Dunn is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: President and Head of R&D, Vima Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Principal AI Architect in the Office of the CTO, at Microsoft. Turning frontier AI into a compounding innovation engine

Cleveland Clinic CIO & Neurology Professor; Executive Lead (Discovery Accelerator) in Quantum computing and AI

Lior Prosor is a Deep33 partner with more than a decade of venture capital investment experience.

Mark Tebbe is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Technology Officer, Spolia Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Co-founder & Chief Product Officer, SolarEdge Technologies

Michael Broukhim is a Deep33 partner and FabFitFun co-founder and co-CEO.

CEO of CX2, serial entrepreneur in autonomous systems

Physics professor at the Weizmann Institute of Science, expert in quantum computing and quantum optics

Investor with 6+ years of VC and M&A experience across Israel and the U.S.; Ex-Arkin, EY, Ceragon, ServiceNow

Owen Hughes is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Executive Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Samantha Singer is listed by Atlas Venture as entrepreneur in residence. The same directory identifies an outside portfolio role: Chief Executive Officer and President, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Scott Ribich is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Scientific Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Investor, former CEO of RENK Group AG; Supervisory Board member at Volkswagen AG, Brenntag SE and BWI GmbH

Investor with 10+ years across AI, product, and deep tech; Ex-8200 Major, AI & Infra lead at Hetz Ventures and Zebra Medical

Yarden Golan is a Deep33 venture partner and former Chief of Staff to Israel’s Minister of Strategic Affairs and to the Israeli Ambassador to the United States.

Robert Hughes, also published as Rob Hughes, is an Atlas adviser and EVP of drug discovery and preclinical development at Rectify Pharmaceuticals. His biography describes earlier molecular-discovery leadership at Disarm and research positions at Boehringer Ingelheim and Pfizer, including neurodegeneration. He earned a Scripps chemistry PhD and an Arizona chemistry/mathematics degree. He is distinct from the STRM.BIO finance executive with the same name.

Andy Mulvaney is listed by Vesper Bio as External Business Development Consultant. Biotechnology business-development executive who co-founded VASTox/Summit and later served as OxStem COO. Holds a Cardiff organometallic-chemistry doctorate and worked in Oxford postdoctoral chemistry research.

Dania Rabah is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Co-Founder and Chief Scientific Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Jared Cumming is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Scientific Officer, Matchpoint Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Jean-François Formela is listed by Atlas Venture as partner. Published educational qualifications include MD, Paris University School of Medicine MBA, Columbia University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment. Bruce Booth’s December5,2024 fund announcement states that Formela remains a partner overseeing his existing portfolio but will not make new Fund XIV investments.

Nello Mainolfi is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer and President, Kymera Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Niranjan Kameswaran is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer, Ethyreal Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Sarah Gerrish is listed by Atlas Venture as executive assistant. Published educational qualifications include BS, cum laude, Plymouth State University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Aimee Raleigh is listed by Atlas Venture as principal. Published educational qualifications include PhD, University of California, San Diego BSE, Duke University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Kristen Margeson is listed by Atlas Venture as vice president of investor relations and marketing. Published educational qualifications include BS, magna cum laude, Simmons College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Peter Barrett is an Atlas partner for legacy funds, with therapeutic-company creation work at Atlas since 2002. He previously co-founded Celera Genomics and held executive and business-development responsibilities there. His own Atlas biography identifies biotechnology board positions and past therapeutic-company investments. He is distinct from Playground Global’s founder Peter Barrett; the two identities and affiliations are preserved separately.

Rubina Parmar is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Head of Technology, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Stella Paffenholz is listed by Atlas Venture as senior associate. Published educational qualifications include PhD, Gerstner Sloan Kettering Graduate School of Biomedical Sciences MS, German Cancer Research Center / University of Heidelberg BS, University of Bonn. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Wenlin Shao is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Development Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Graham Wynne is listed by Vesper Bio as External Medicinal Chemistry Consultant. Founder of930 Consulting, advising medicinal-chemistry and drug-discovery projects. Holds a Nottingham organic-chemistry doctorate and undertook postdoctoral research at the Australian National University.

Jørgen Erik Nielsen is listed by Vesper Bio as Scientific Advisor. University of Copenhagen clinical professor in neurology based at Rigshospitalet. This clinician is distinct from the deceased literary scholar of the same name; detailed education is not stated by the current official directory.

James B. Rowe is listed by Vesper Bio as Scientific Advisor. Cambridge cognitive-neurology professor studying Alzheimer’s disease, frontotemporal dementia and related disorders. Trained at Cambridge, Oxford and UCL, followed by specialist neurology training in London/Copenhagen; directs Cambridge’s FTD centre.

John King-Underwood is listed by Vesper Bio as External Medicinal Chemistry Consultant. Computational-chemistry consultant working with medicinal chemistry, molecular modelling, structure-based design, virtual screening and informatics; own XPose directory confirms the same named computational-chemistry adviser.

Akshay Vaishnaw is listed by Atlas Venture as venture partner. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Caroline Breitbach is listed by Atlas Venture as entrepreneur-in-residence. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Evan Thackaberry is listed by Atlas Venture as entrepreneur-in-residence. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Geraldine Harriman is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Co-Founder and Chief Scientific Officer, HotSpot Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Jeff Trigilio is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Financial and Chief Business Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

John Cox is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: President and Chief Executive Officer, Dyne Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

David Grayzel is listed by Atlas Venture as partner. Published educational qualifications include MD, Harvard Medical School BA with honors, Stanford University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Katharine Unangst is listed by Atlas Venture as executive assistant. Published educational qualifications include Palm Beach State College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Maurizio Fazio is listed by Atlas Venture as principal. Published educational qualifications include PhD, Harvard University MD, cum laude with honor mention, Vita-Salute San Raffaele University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Rajesh Devraj is listed by Atlas Venture as venture partner. The same directory identifies an outside portfolio role: President & Chief Executive Officer, Rectify Pharmaceuticals. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Vito Palombella is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Scientific Officer, TRIANA Biomedicines. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Eben Tessari is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Executive Officer, Calixis. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Praveen Tipirneni is listed by Atlas Venture as venture partner. The same directory identifies an outside portfolio role: Chief Executive Officer, Caldera Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Eric J. Huang is listed by Vesper Bio as Scientific Advisor. WashU pathology/immunology chair and neuropathologist studying neural development and neurodegeneration. MD from National Taiwan University, Cornell/Sloan-Kettering doctorate and UCSF neuropathology/postdoctoral training. This is distinct from Delos investor Eric Huang.

Eric Schmid is listed by Atlas Venture as vice president, legal affairs. Published educational qualifications include JD, magna cum laude, Boston College Law School BA, Wake Forest University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Jonathan Rohrer is listed by Vesper Bio as Scientific Advisor. UCL-associated neurologist researching young-onset and genetic dementias. Studied natural sciences at Cambridge and medicine at Oxford/UCL, with specialist neurology training in London.

Justin Feng is listed by Atlas Venture as senior associate. Published educational qualifications include PhD, Harvard University BS with High Honors, University of California, Berkeley. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Shelia Violette is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Founder, Chief Scientific Officer, President of Research, Q32 Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Steve Finkbeiner is listed by Vesper Bio as Scientific Advisor. UCSF neurology professor researching neuronal plasticity, memory and neurodegeneration, including Huntington’s disease. Trained in medicine/neuroscience at Yale and neurology at UCSF.

Steven Robinette is listed by Atlas Venture as venture partner. The same directory identifies an outside portfolio role: Chief Executive Officer, Spolia Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Kevin Bitterman is listed by Atlas Venture as partner. Published educational qualifications include PhD, Harvard Medical School BA with highest honors, Rutgers University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Mike Forkel is listed by Atlas Venture as vice president, finance. Published educational qualifications include MBA, Boston College Carroll School of Management BA, College of the Holy Cross. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Phillip Samayoa is listed by Atlas Venture as venture partner. The same directory identifies an outside portfolio role: Chief Operating Officer, Ethyreal Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Bob Copeland is listed by Atlas Venture as venture partner. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Constantine Chinoporos is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Executive Chairman, Rectify Pharmaceuticals. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Julia Pian is listed by Atlas Venture as senior associate. Published educational qualifications include MD, Harvard Medical School MBA, Harvard Business School AB, summa cum laude, Harvard College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Kathy Doherty is listed by Atlas Venture as receptionist. Published educational qualifications include Charlestown High School. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Laura Alessio is listed by Atlas Venture as director of portfolio operations. Published educational qualifications include BSBA, Middlesex College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Vishal Patel is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer, Triveni Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Eleanor Ronan is listed by Atlas Venture as manager of talent and hr operations. Published educational qualifications include BS, University of Richmond. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Diana Brainard is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Executive Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Jason Rhodes is listed by Atlas Venture as partner. Published educational qualifications include MBA, Wharton BA, Yale University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Natalia Misciattelli is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer, AAVantgarde Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Peter Smith, also published as Pete Smith, is co-founder, president and CEO of Remix Therapeutics and an Atlas adviser. His biography describes earlier scientific leadership at H3 Biomedicine and oncology drug discovery at Takeda and Millennium. He completed a Newcastle University PhD and postdoctoral research at Dana-Farber. He is distinct from the EQT infrastructure investor with the same name.

Alex Lugovskoy is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer, Diagonal Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Brenton Mar is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Medical Officer, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Diana Francis is listed by Atlas Venture as controller. Published educational qualifications include MST, Bentley University BS, magna cum laude, Bentley University. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Jonathan Montagu is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Executive Officer, HotSpot Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Meaghan Gallagher is listed by Atlas Venture as executive assistant. Published educational qualifications include BA, Assumption College. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Alfica Sehgal is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Scientific Officer, Judo Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Douglas Kerr is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Chief Medical Officer, Dyne Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Farah Lewis is listed by Atlas Venture as executive assistant. Published educational qualifications include BA, Tufts University B.Mus, New England Conservatory. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Haojing Rong is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Chief Development Officer, Spolia Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Simon Read is listed by Atlas Venture as venture partner. The same directory identifies an outside portfolio role: Acting Chief Executive Officer, Judo Bio. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Timothy P. Reilly is listed by Atlas Venture as entrepreneur-in-residence. The same directory identifies an outside portfolio role: Head of R&D, Stealth NewCo. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Olivier Heckmann is identified in Anaxago’s public group governance directory as Administrateur. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand.

Arnaud Giraudon is identified in Anaxago’s public group governance directory as Administrateur. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand.

Patrice Hutin is identified in Anaxago’s public group governance directory as Administrateur. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand.

Guillaume Regert is identified in Anaxago’s public group governance directory as Directeur de l'Investissement et de l'Asset Management. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand. Guillaume Regert is published as Director of Investment and Real Estate Asset Management by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Bruno Blanc is identified in Anaxago’s public group governance directory as Directeur Général Adjoint. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand. Bruno Blanc is published as Deputy Managing Director by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Chloë Brun is identified in Anaxago’s public group governance directory as Présidente d'Anaxago et d'Anaxago Patrimony. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand.

Guillaume Dupont is identified in Anaxago’s public group governance directory as Directeur Général Anaxago Capital. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand. Guillaume Dupont is published as Venture Partner — CapHorn venture brand by the CapHorn venture-capital brand. The own biography identifies him as founder of CapHorn in2011 and describes over20 years in venture capital; the heading currently says Venture Partner while older body text says Managing Partner.

Joachim Dupont is identified in Anaxago’s public group governance directory as Président Anaxago Capital. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand. Joachim Dupont is published as President by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Caroline Lamaud is identified in Anaxago’s public group governance directory as Présidente Conseil d'Administration. The record uses the official named portrait adjacent to this person’s card. This is the published group affiliation; exact legal employing subsidiary and any later changes are not assumed. Anaxago Capital roles on the legacy directory are qualified by the December2025 Ambra rebrand.

Anaxago SAS is the French crowdfunding investment platform established in 2012, RCS Paris 539 539 064, registered at 18 rue Sainte-Foy, Paris. Its own legal disclosures identify AMF crowdfunding-services authorization FP-2023-25. It arranges club deals and access to unlisted healthcare, climate and real-estate investments for a community of private and professional subscribers. Investment relationships recorded for this platform represent explicitly disclosed collective subscriber participation; they are not assertions that Anaxago paid the subscriber aggregate from its own balance sheet. Individual member and legal holding-company allocations remain unpublished. Its separate regulated asset-manager affiliate was Anaxago Capital, RCS 840 861 397 and AMF GP-18000016, formed in 2018; that manager and CapHorn Invest adopted the common Ambra Capital brand in December 2025. Anaxago Patrimony is a distinct advice business. Manager funds, accumulated platform investment volumes and client assets are not platform fund closes. The own public group directory names nine governance/executive professionals. Affiliations explicitly labeled Anaxago Capital in that directory are retained as qualified published group affiliations because the directory predates or has not been harmonized with the Ambra rebrand; they are not claims of current employment at an independent old manager. Chloë Brun is identified as president of the crowdfunding platform and Patrimony; a recruitment page instead uses the older director-general title. Anaxago reports its investor community supported Acticor Biotech in four financings in 2015, 2016, 2017 and 2019. That historical promotional page predates Acticor’s January 2025 judicial liquidation and failed 2024 stroke-trial efficacy endpoints; its old clinical optimism and unrealized performance are not current efficacy or valuation statements.

Anna Ravnefjord is currently listed by Vesper Bio as REGULATORY AFFAIRS SPECIALIST. Works in regulatory affairs for investigational drug development; current role is source-qualified without invented education.

Tina Vig is currently listed by Vesper Bio as SENIOR CLINICAL TRIAL MANAGER. Manages clinical trials of the company’s investigational neuroscience programmes; no full appointment date is disclosed.

Anders Riisager is currently listed by Vesper Bio as SENIOR PROJECT MANAGER. Coordinates Vesper scientific-development projects; no unverified academic qualification or historical start date is inferred.

Brittany Lo Cicero is currently listed by Vesper Bio as EXECUTIVE ASSISTANT AND OFFICE MANAGER. Supports leadership, office operations and internal communications.

Lærke Fensbæk is currently listed by Vesper Bio as ASSOCIATE CLINICAL TRIAL MANAGER . Coordinates clinical trials at the Copenhagen investigational CNS-drug developer; detailed academic credentials are not asserted.

Imogen Swift is currently listed by Vesper Bio as SENIOR RESEARCH SCIENTIST. Works on neuroscience research and clinical-development programmes; academic history is not established by the current employer profile.

Mads Kjølby is currently listed by Vesper Bio as FOUNDER & CMO. Cofounder and chief medical officer overseeing clinical development, with more than a decade of clinical-pharmacology experience and specialist sortilin research.

Louise Klem is currently listed by Vesper Bio as LEAD RESEARCH SCIENTIST. Investigates sortilin inhibition and progranulin in neurodegeneration; issuer identifies her as principal investigator of its2024 MJFF Parkinson’s grant.

Lovisa Sunesson is currently listed by Vesper Bio as DIRECTOR OF BUSINESS DEVELOPMENT. Works across fundraising, partnering and company promotion in neuroscience-focused biotechnology.

George Varvarelis is currently listed on Skybound Venture Capital’s published team as General Partner. The firm backs pre-seed and seed-stage deep-technology companies.

Ivana Henckel von Donnersmarck is currently listed on Skybound Venture Capital’s published team as VP (published acronym; expansion unconfirmed). The firm backs pre-seed and seed-stage deep-technology companies.

Natalie Dayan is currently listed on Skybound Venture Capital’s published team as Associate. The firm backs pre-seed and seed-stage deep-technology companies.

Thaleia Misailidou is currently listed on Skybound Venture Capital’s published team as General Partner. The firm backs pre-seed and seed-stage deep-technology companies.

Nina Schultz is currently listed by Vesper Bio as PRINCIPAL RESEARCH SCIENTIST. Works on Vesper’s preclinical neurodegeneration and sortilin-inhibition research; detailed education is not published in the current company biography.

Ove Pedersen is currently listed by Vesper Bio as SVP OF CMC & PRECLINICAL DEVELOPMENT. Oversees clinical-trial medicine development/manufacturing, active-ingredient safety testing and quality assurance; previously served Vesper as chemistry/manufacturing consultant.

Sofie Let Frandsen is currently listed by Vesper Bio as SENIOR RESEARCH SCIENTIST. Designs and coordinates preclinical in-vivo and in-vitro neurodegeneration studies investigating sortilin inhibition.

Alvin Asper is listed by Geodesic Capital as Chief Financial Officer. Manages finance, reporting and audit after controller work at Kleiner Perkins and fund accounting at Mayfield.

Arvind Ayyala is listed by Geodesic Capital as Partner. Invests in enterprise software, fintech, healthcare and sustainable technology; previously worked at EDBI.

Brent Wu is listed by Geodesic Capital as Partner; Manages Investor Relations. Manages investor relations after leading business development at Kespry and Blackhawk Network.

Chick Runkel is listed by Geodesic Capital as Project Manager. Manages projects after a career in IBM sales, marketing and management.

Divya Sudhakar is listed by Geodesic Capital as Partner. Invests in enterprise software after investment roles at Intel Capital and In-Q-Tel.

Etsuko Aoyama is listed by Geodesic Capital as Manager of Events Marketing. Plans and runs Geodesic Forum and other events; previously led event programmes at JTB USA and JAPAN HOUSE Los Angeles.

Hyesu Sai is listed by Geodesic Capital as Manager of Events and Marketing (Geodesic Japan, G.K. group affiliation). Plans Japan events, produces the Geodesic Japan Newsletter and supports portfolio-company marketing; previously worked at JTB Communication Design.

James Kondo is listed by Geodesic Capital as Senior Advisor. Advises on technology, management and policy; chairs International House of Japan and previously led Twitter Japan.

Jessica Lazos is listed by Geodesic Capital as Executive Assistant. Supports founding partner John Roos and U.S. office administration after administrative and marketing work at Carr McClellan.

John Roos is listed by Geodesic Capital as Founding Partner. Previously U.S. Ambassador to Japan and CEO of Wilson Sonsini Goodrich & Rosati. Current Salesforce primary-source qualification: John V. Roos is a Salesforce board director. Roos is Former U.S. Ambassador to Japan; Co-Founder, Geodesic Capital at Salesforce. He has served on Salesforce’s board since September 2013. He was US ambassador to Japan from 2009 to 2013 and later co-founded Geodesic Capital, focusing on growth-stage technology investing.

Jon Rezneck is listed by Geodesic Capital as Partner, Head of Investment Team and Chief Operating Officer. Covers fintech and previously worked in investment banking at Greenhill and JP Morgan.

Joshua Parker is listed by Geodesic Capital as Associate (Alliance Fund). Focuses on early-stage deep technology and energy resilience after Teneo consulting and technology investment banking.

Justin Yue is listed by Geodesic Capital as Senior Associate. Works on deal sourcing, execution and portfolio support after technology investment banking at Bank of America.

Kurt Tong is listed by Geodesic Capital as Senior Advisor. Advises Geodesic while serving as The Asia Group managing partner; previously a U.S. diplomat in Japan and Hong Kong.

Marcus Otsuji is listed by Geodesic Capital as Country Manager (Geodesic Japan, G.K. group affiliation). Leads the Japanese portfolio-support operation; previously held country leadership and sales roles at Omniture and Apple Japan.

Masashi Oka is listed by Geodesic Capital as Senior Advisor. Advises Geodesic after financial and technology leadership at MUFG, Nikon and Sony Financial Group.

Matt Fuller is listed by Geodesic Capital as Partner; Leads Investor Relations, Fundraising and International. Previously an American diplomat, including service on the White House National Security Council.

Neb Mela is listed by Geodesic Capital as Partner. Nebiu (Neb) Mela invests in AI, advanced manufacturing, healthcare, energy and robotics after Tishman Speyer Ventures and Intel Capital.

Rayfe Gaspar-Asaoka is listed by Geodesic Capital as Partner (Alliance Fund). Invests in early-stage AI, space, cybersecurity and autonomy after serving as a Canaan partner.

Shiro Watanabe is listed by Geodesic Capital as Director, LP Digital Strategy (Geodesic Japan, G.K. group affiliation). Helps limited partners identify technology-business partners; previously worked on venture investments and cross-border M&A at Macnica.

Stavroula Cannon is listed by Geodesic Capital as Administrative Assistant and Office Manager. Supports the U.S. office and previously managed executive assistance and facilities work in real estate and biotechnology.

Susie Roos is listed by Geodesic Capital as Partner and Chief Administrative Officer. Previously an employment and labour attorney; helped found the TOMODACHI initiative.

Suzanne Basalla is listed by Geodesic Capital as Partner (Alliance Fund). Works on the Alliance Fund after leading the U.S.-Japan Council and serving as Toyota Research Institute chief of staff.

Takayuki Otsuka is listed by Geodesic Capital as Director of Business Development (Geodesic Japan, G.K. group affiliation). Supports portfolio companies with Japanese go-to-market strategy after sales and product roles at Apple, Microsoft, Nokia and JVC.

Will Horyn is listed by Geodesic Capital as Principal. Sources and executes enterprise-software investments; previously worked on Cisco acquisitions and venture investments.

BOM, the Brabant Development Agency, combines venture development, patient venture capital and international business support to help innovative companies grow in Noord-Brabant. It invests early in scalable startups and scale-ups, typically EUR200,000–EUR5 million per company, and works with private co-investors. Its investment focus includes deep technology and AI, medical technology and life sciences, decentralized energy and plant-based innovation. The BOM platform operates through Brabantse Ontwikkelings Maatschappij Holding B.V. and its group companies, with separate venture-investment and renewable-energy investment committees. BOM also manages the national SecFund on behalf of the Dutch regional development agencies, financing early-stage dual-use technology for civilian and defense applications.

RTX Ventures is the corporate venture capital arm of RTX, investing in early-stage companies developing technology for aerospace and defense. Its focus includes advanced manufacturing, autonomy and sensing, computing, data and software, propulsion and aviation, and space. Portfolio companies can work with RTX through supply and licensing agreements, research and development, access to products and services, and joint commercial development. The unit launched in 2022. No separately announced new fund launch or completed fund corpus in the last three years was verified; annual investment deployment is not a fund close.

President and Managing Director at RTX Ventures, the corporate venture capital arm of RTX.

Director at RTX Ventures, the corporate venture capital arm of RTX.

Executive Assistant at RTX Ventures, the corporate venture capital arm of RTX.

Senior Director at RTX Ventures, the corporate venture capital arm of RTX.

Executive Director at RTX Ventures, the corporate venture capital arm of RTX.

Director at RTX Ventures, the corporate venture capital arm of RTX.

Executive Director at RTX Ventures, the corporate venture capital arm of RTX.

Director at RTX Ventures, the corporate venture capital arm of RTX.

Aero X Ventures (AXV) is an operator-led venture capital firm investing in early-stage deep technology for aviation, aerospace and defense. It backs autonomy, artificial intelligence and edge compute, robotics, new aircraft and propulsion, and space infrastructure. The firm combines investment diligence with portfolio engagement, strategic introductions and commercial and government market support. On March 30, 2026 it announced AXV Fund II, anchored by Seabury Capital Ventures and targeting USD 100 million in LP commitments; the target is not a reported completed fund size.

Technology strategist with a decade building, funding, and acquiring aerospace technologies. Former Tech Acquisitions & Strategy Advisor at Booz Allen advising USAF procurement; systems engineer at Northrop Grumman and Raytheon.

Co-Founder & Principal, Salt + Vinegar. Three decades across media, entertainment, brands, and technology, with clients from Hulu and Adidas to Universal Music Group. Now advises family offices and sovereign wealth funds across MENA, and Singularity Capital Advisors on defense and national security. UCLA.

Lieutenant Colonel, U.S. Army. 20 years in Special Operations, aviation, and intelligence. Rated AH-64 / UH-60 pilot, four combat deployments. Wharton MBA; Penn JD.

VP, Global Sales Consulting, Trintech. 15 years in sales consulting and digital transformation for government and firms including Stripe, Uber, and Peloton. Wharton EMBA.

Principal, Stella Maris Strategies. Distinguished Naval Aviator; commanded HSC-85 and later served as Chief of Staff of NASA. Harvard MPP; Wharton MBA.

Founder & President, AeroX. Built NCDOT’s award-winning UAS program and led its FAA Integration Pilot Program. NASA Aeronautics R&T Roundtable appointee.

Founder & CEO, Approach Venture. Advises frontier-tech founding teams; background across A&D banking, venture, and defense-tech operating roles. U.S. Naval Academy.

Founder & CEO, growth[period]. Guided 250+ commercial and federal companies through BD and M&A. Former Corporate VP of Homeland Security at Raytheon.

Chief Executive Officer, Triman Holdings. Defense and aerospace supply-chain and logistics. Former VP Ops at MAG Aerospace; 23-year USAF KC-10 pilot. Wharton MBA.

Chairman & CEO (Ret.), Serco Inc.. Led a $1.5B government-services firm of ~8,000. 30+ years across Lockheed Martin Skunk Works, Raytheon, and VT Group.

Chief Technology Officer, Crown Consulting. 35-year NASA Ames career concluding as deputy center director; pioneered unmanned traffic management. Ph.D., Stanford.

Drives investment diligence, sector research, and portfolio monitoring across the firm’s focus areas.

President & CEO, JANUS Research Group. Former President & CEO of TCOM, the persistent-surveillance aerostat manufacturer. Two decades leading engineering and growth across defense and industrial technology.

As Aero X Ventures’ Head of Platform, Jay Velasco led portfolio engagement, community and events, and LP strategic partnerships. He publicly announced his final day at the firm on October 2, 2026.

Supports investment research, due diligence, and deal evaluation. Previously at Graham Partners in private equity. Licensed pilot and founder of Fly Beyond Boundaries, a nonprofit that has raised $28,000+ for aviation education in Montana.

Major General, U.S. Army (Ret.). 33rd Commander of the Army JFK Special Warfare Center & School; Commanding General, CJTF–Horn of Africa. West Point.

Co-founder and CIO; previously Portfolio Manager at iGnosis Capital. An operator who ran FAA Part-135, -141, and -145 aviation businesses and led fintech Zingo to a strategic exit. Eight years at Wells Fargo.

Oversees fund and transaction legal operations, entity governance, and compliance across the platform.

Founder & Partner, Osprey Capital · Chairman, AeroX. Former President & COO of B/E Aerospace, leading the supplier to a strategic exit to Boeing and Rockwell Collins. MBA, Harvard.

Evaluates opportunities across aerospace, defense, and technology. Previously at Lockheed Martin on naval defense systems, specializing in counter-UAS detection and directed energy. FAA Part 107 Remote Pilot; B.S. Aerospace Engineering, Penn State.

Founder & First President, UPS Flight Forward. Holder of the first Standard Part-135 air-carrier certificate for drones in U.S. history. 37-year UPS career.

Founder & CEO, Carrack Capital. Founder & CEO of Carrack Capital, building liquid, diversified portfolios for cash management and long-term wealth. 15+ years in quantitative investment management, previously Head of Public Markets at Drake Capital and a Director at Ziff Brothers Investments, with earlier roles at BlackRock. Wharton MBA; CFA.

Senior Aerospace & Defense Executive. 25 years across defense, national security, aerospace, and intelligence, directing over $12B in strategic programs. Formerly CIA, ITT, Lockheed Martin, and Accenture Federal Services. Wharton MBA; JM, Scalia Law.

Co-Founder & CEO (Ret.), Apogee Engineering. Grew Apogee from $1M to $20M in revenue and 750 employees across 36 states, through 8(a) graduation to its 2024 sale. Earlier at Booz Allen, Lockheed Martin, and General Dynamics on Milstar satellite programs.

Vesper Bio ApS is a Copenhagen clinical-stage biotechnology company developing investigational oral small-molecule sortilin inhibitors for neuropsychiatric and neurodegenerative disease. Its lead brain-penetrant candidate VES001 is being studied for frontotemporal dementia associated with progranulin-gene mutations; the company’s mechanism targets sortilin-mediated progranulin degradation. Clinical results are issuer-reported research findings, not regulatory approval or established therapeutic benefit. Its current own directory publishes fourteen staff, three external medicinal-chemistry/business-development consultants and seven scientific advisers. Founder and chief scientific officer Anders Nykjær and cofounder/chief medical officer Mads Kjølby are separately identified; Jacob Falck Hansen was appointed CEO in July2025. The Lundbeck Foundation’s audited2024 group overview lists Vesper Bio as its direct subsidiary, rather than an associate of Lundbeckfond Invest A/S. A November17,2025 USD2.5M mission-related strategic investment is attributed to ADDF and AFTD through their joint Treat FTD programme; per-buyer allocations and cash payment schedule are undisclosed. A January23,2024 MJFF award is approximately USD873000 and is not equated with cash paid. This Danish company is distinct from the unrelated Brazilian venture builder at vesper-bio.com.

Texas Medical Center Venture Fund (TMCVF) is the venture capital arm of Texas Medical Center Corporation, funded through the corporation. It backs early-stage healthcare companies developing digital health tools, medical devices and therapeutics, from pre-seed through Series A. Alongside capital, the platform helps founders engage with the Texas Medical Center’s clinical, research and commercialization ecosystem. Its healthcare investments include medical-device engineering, diagnostics, neuroscience and AI-enabled care and operations tools. Launched in 2017, the fund operates as an evergreen investment programme; the current website reports USD75 million, while a separately dated March 29, 2022 announcement reported its expansion from USD25 million to USD50 million.

Works on the venture fund and strategic projects at Texas Medical Center. Previously led TMC accelerator programs and studied cancer immunotherapy drug delivery during her Rice University bioengineering doctorate.

Evaluates therapeutics and medical-device investments for the fund. Holds a UCLA neuroscience doctorate focused on microbiome and nervous-system interactions and a neuroscience bachelor’s degree from UT Austin.

Oversees the fund’s investment diligence while leading strategy and new ventures at Texas Medical Center. Previously worked at Cart.com, McKinsey and Schlumberger.

Leads the parent organization’s innovation activities. Previously led JLABS at TMC and held research and business development roles at Shire and Johnson & Johnson Innovation.

President and CEO of the parent Texas Medical Center, with previous healthcare leadership roles at Medtronic, MicroPort and Cellnovo. His fund biography explicitly lists a TMC Venture Fund board seat.

Peter Savitscus was head of trading in Tekla’s own2017 manager presentation. It identifies Villanova education and prior Merrill Lynch experience, with responsibility for trading operations and technical research. Current independent Tekla employment is not inferred.

Alan Kwan was a Tekla senior analyst in its2017 presentation, with Washington University PhD/MBA training and prior GlaxoSmithKline experience. His published research areas included life-science tools, diagnostics and medical technology. This is a historical manager role.

Amanda Benson was a senior analyst in Tekla’s own2017 presentation, with Dartmouth PhD training and prior R.A. Capital experience. Her published areas included dermatology, women’s health and biotechnology. This supports a dated historical role rather than current2026 employment.

Christian Richard was a senior vice president in Tekla’s own2017 manager presentation. It identifies New York University MBA training, prior Merlin Biomed and Schering-Plough Research Institute experience, and coverage of cardiovascular disease, biosimilars, inflammation and venture/PIPE investments. This is a historical affiliation.

Graham Attipoe, MD and MBA, is named in the Tekla Healthcare Investors March2023 investment research team. The exact dated primary institutional role is retained; no unverified current position, employment start/end day or individual investment is inferred.

Joshua Mosberg was a Tekla senior analyst in its2017 presentation, with Washington University/Harvard PhD training and prior Clarion Healthcare experience. The manager identified biotechnology and small-cap therapeutics as his research areas. The source does not establish current2026 employment.

Christopher Seitz joined Tekla in2021 as vice president of research. Its2023 fund filing documents earlier Nantahala Capital Management healthcare analyst internship and Excel Venture Management associate experience, followed by an October2023 transition to abrdn as investment director. The historical role does not establish current 2026 Tekla employment.

Jack Liu, PhD and MBA, was named in the investment team analyzing investments for Tekla Healthcare Investors in its March2023 shareholder report. That primary record supports the historical investment role; exact subsequent employer, employment dates and personal investment amounts are not inferred.

Richard Goss joined Tekla in2018 as vice president of research. The2023 fund filing documents prior Leerink Partners large-pharmaceutical/biotechnology equity research and Datamonitor healthcare analysis, and his move to abrdn as investment director inOctober2023. This is a historical manager affiliation, distinct from personal equity allocations.

Ashton Wilson joined Tekla in2018 and served as senior vice president. The2023 fund filing identifies prior Goldman Sachs equity-derivative trading and Bank of America Merrill Lynch experience, followed by an October2023 move to abrdn as senior investment director. Exact current employment beyond the reviewed dated disclosures is not inferred.

Christopher Abbott joined Tekla in2016 and served as vice president of research, previously a Leerink Partners equity research vice president. The2017 manager presentation identifies Hamilton College education and healthcare services/information technology research. The2023 filing documents his October2023 transition to abrdn as investment director.

Timothy Gasperoni joined Tekla in2015 and served as senior vice president of research. The manager’s2017 presentation identifies UCLA/MIT training, CNS, gastrointestinal and specialty pharmaceutical research, and structured deals. The2023 transition filing documents prior Sabby Capital founding/research, Crosswind and Andesite experience and his October2023 move to abrdn. This is a dated career biography, not a current independent Tekla affiliation.

Daniel R. Omstead led Tekla Capital Management and its four healthcare funds. The manager’s 2017 presentation identifies him as president and CEO with Columbia University training. The 2023 filings identify him as the investment decision maker and document transition to abrdn Inc. His announced successor Jason Akus took over the lead portfolio manager role in June2024, with Omstead’s advisory transition envisaged through September2024; this is not a claim of current 2026 Tekla employment.

Henry Skinner is the Chief Executive Officer of the AMR Action Fund, with a background in microbiology, drug-development investing and pharmaceutical business development. His current own biography confirms prior leadership at Tekla Capital Management and Novartis Venture Fund and CEO roles at SelectX and NeoGenesis Pharmaceuticals. He earned a microbiology PhD and biochemistry MS at the University of Illinois, with additional bioethics/health-law training. Arkuda’s archived2021 company biography names him as a board member and then Tekla Senior Vice President of Venture; the Arkuda affiliation and Tekla title are historical, not assertions of current employment.

Shawna Henry was publicly named by Arkuda Therapeutics as Scientist I. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Stephanie McTighe was publicly named by Arkuda Therapeutics as Director, Pharmacology. She developed pharmacological models and quantitative studies of candidate compounds with the biology team. Her prior role was head of in-vivo pharmacology at Sage Therapeutics. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Irena Webster was publicly named by Arkuda Therapeutics as Vice President, Program Strategy & Dev Ops. She joined Arkuda in April2023 with about two decades of global drug-development experience, including Forma Therapeutics, Sage Therapeutics and Alkermes, and clinical operations across CNS and other therapeutic areas. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Joanna Bryce was named Chief Financial Officer of Arkuda Therapeutics by company co-founder/investor Bruce Booth in November2019, providing financial support to the progranulin/lysosomal drug-discovery company. This is a dated historical appointment; continued Arkuda employment after2019 is unverified.

Mike Esposito was publicly named by Arkuda Therapeutics as Vice President, Finance. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Raymond Hurst was publicly named by Arkuda Therapeutics as Senior Vice President, Discovery. He became Senior Vice President of Discovery in April2023 after serving as Arkuda VP of Pharmacology since2020. His background includes Concert Pharmaceuticals and more than20years in CNS drug discovery. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Serena Hung was publicly named by Arkuda Therapeutics as Chief Medical Officer. She is a neurologist with movement-disorder training and experience in clinical development. Atalanta Therapeutics appointed her Chief Medical Officer May22,2024 and explicitly describes Arkuda as a former employer. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Duane Burnett was publicly named by Arkuda Therapeutics as Co-Founder and Chief Technology Officer. He co-founded Arkuda in2018 and became Chief Technology Officer in April2023 after leading discovery. His background includes CNS and cardiovascular medicinal chemistry at Schering-Plough, Merck and FORUM Pharmaceuticals; he contributed to the invention of ezetimibe. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Betsy Kassler was publicly named by Arkuda Therapeutics as Senior Director, Human Resources. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Xiaowen Peng was publicly named by Arkuda Therapeutics as Director, Medicinal Chemistry. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Katie Watters was publicly named by Arkuda Therapeutics as Scientist I. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Mary Wozniak was publicly named by Arkuda Therapeutics as Senior Research Associate. She investigated how reduced progranulin affects FTD-GRN. Her biography identifies a behavioral-neuroscience degree from Northeastern University and industry neurodegeneration research experience. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Morgan Brand was publicly named by Arkuda Therapeutics as Associate Scientist. She profiled candidate compounds with chemistry and pharmacology colleagues and contributed to target-identification work. Her background includes Celgene and a chemistry/biology degree from Roger Williams University. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Richard Gallegos was publicly named by Arkuda Therapeutics as Principal Scientist, DMPK. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Veronika Heil was publicly named by Arkuda Therapeutics as Associate Scientist. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Hillary Van Voorhies was publicly named by Arkuda Therapeutics as Director, Program Management. She coordinated programmes moving from research into development. Her experience included Alkermes and FORUM Pharmaceuticals and an MS from UMass Amherst. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Ingrid Ochoa was publicly named by Arkuda Therapeutics as Lab/Facility Manager. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Jean-François Blain was publicly named by Arkuda Therapeutics as Vice President, Neurobiology. He led exploratory biology investigating progranulin and neurodegenerative disease. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Jim Lanter was publicly named by Arkuda Therapeutics as Vice President, Medicinal Chemistry. He collaborated with external medicinal-chemistry groups across two continents and brought more than two decades of synthetic chemistry experience across therapeutic modalities. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

John Ross was publicly named by Arkuda Therapeutics as Associate Director, Toxicology. He directed nonclinical safety work for drug-discovery programmes after experience managing toxicology and safety-pharmacology studies at a CRO. He holds an MS in toxicology and safety pharmacology from Wright State University. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Christopher Holler was publicly named by Arkuda Therapeutics as Principal Scientist. He helped develop assays for progranulin expression and function in the FTD-GRN discovery programme. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Deliwe Jalbert was publicly named by Arkuda Therapeutics as Executive Assistant. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Denise Peters was publicly named by Arkuda Therapeutics as Accounting Controller. She managed accounting and financial operations after nearly two decades working with medical-device, life-science and biopharma companies. She studied accounting at Nashville State Community College. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Gennifer Greenberg was publicly named by Arkuda Therapeutics as Senior Research Associate. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Giuseppe Astarita was publicly named by Arkuda Therapeutics as Senior Director, Biomarker Dx. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Angela Chen was publicly named by Arkuda Therapeutics as Scientist II. Her work included biological screening, compound inventories and coordination of outsourced PK/PD studies and animal colonies. Her biography describes over a decade of neurodegeneration research experience. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Anna-Maria Alves was publicly named by Arkuda Therapeutics as Associate Scientist. She developed progranulin assays and evaluated potential therapies. Her background includes Sanofi-Genzyme and Navitor Pharmaceuticals and an MS in cellular and molecular biology from UMass Amherst. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Bonne Thompson was publicly named by Arkuda Therapeutics as Scientist II, Mass Spectrometry. The published company roster establishes this specific role; additional education and employment history are not disclosed in that biography. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Robert Urban was publicly named by Arkuda Therapeutics as Independent Board Member. He is a former Johnson & Johnson Innovation global leader, retiring from that role in2018 after an international healthcare career. His Arkuda board seat was independent, not proof of a personal investment or institutional funding allocation. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Ash Khanna is Chief Business Officer of Tentarix Biotherapeutics, appointed in September2025, following a partner role at Pivotal bioVenture Partners. His career includes co-founding Vaxcyte and leading its business development and financing activities, venture investing at SV Health Investors and scientific work at Bristol Myers Squibb. He has a pharmacology PhD from SUNY Buffalo and a Wharton MBA and contributed to the invention of saxagliptin/Onglyza. Arkuda’s archived2023 company roster names him as a board member with a contemporaneous Pivotal title; that affiliation is historical and does not establish current Arkuda board membership or a personal investment.

Denis Patrick is published by Pfizer Ventures as Managing Partner (2025 published roster; current directory omission qualified). Pfizer’s own2025year-in-review namesDenisPatrick asManagingPartner. The live2026twelve-person directory omits him; exact ongoingtenure ordepartureday is not independentlyestablished. The separate issuerMissionTherapeutics published biography describes oncology research atMerck,DuPontPharma andGSK,biochemistry educationatSUNY/UniversityofPennsylvania andbiologyMSatUCSD. These are careerfacts, notpersonal checks or currentoutsidecompanyboardappointments.

Sophia Wood is published by Pfizer Ventures as Executive Assistant. Sophia Wood is the Executive Assistant for the Pfizer Ventures team. Sophia joined the team in 2018 and serves as the core administrative partner managing complex schedules, coordinating high-stakes meetings, and ensuring seamless operations that drives team efficiency. Prior to joining Pfizer, Sophia held various administrative roles at companies including Mount Sinai School of Medicine, NYU Langone Medical Center, St. Vincent’s Medical Center, and Memorial Sloan-Kettering Cancer Center.

Ama Amoah is published by Pfizer Ventures as Finance Director, Business Development. Ama Amoah is the Finance Director, Business Development and serves as the business finance leader on equity investments decisions, partnering with the Pfizer Ventures and Pfizer Breakthrough Growth Initiative teams. She also serves as the primary finance point of contact for business development deals, providing financial leadership on external development opportunities and offering business consultation and analytical support throughout all stages of the BD process. Most recently, Ama provided financial leadership, business consultation, thought partnership and analytical support to the Pfizer Ignite business. She also managed central deals investment decisions within the Pfizer Research and Development Discovery and Early Development organization. Ama rejoined Pfizer in 2019 and supported the I&I RU, Investor Relations, and various teams in the legacy Global Product Development and Worldwide Safety organizations. Previously, she worked for Royal Dutch Shell in Norway, where she performed valuation analyses for JV assets, and led negotiations for long-term gas contracts. Ama holds a BSc in Chemistry from McMaster University and received her MBA from Simmons Graduate School of Management.

Boyoon Choi is published by Pfizer Ventures as Senior Corporate Counsel. Boyoon Choi is Senior Corporate Counsel at Pfizer. Since joining Pfizer in 2021, Boyoon has served as co-counsel to Pfizer Ventures, providing transactional and general legal advice in connection with its equity investing and portfolio management activities. Boyoon has advised on numerous equity and debt financings of both private and public companies as well as strategic fund investments by Pfizer. Boyoon also represents Pfizer in connection with M&A transactions, divestitures and licenses, including most recently the acquisition of Seagen. Prior to joining Pfizer, Boyoon was legal counsel for a global diversified pharmaceutical company, including its corporate venture arm, and an asset manager with over $900 billion in assets under management. Boyoon holds a J.D. from Columbia University (Harlan Fiske Stone Scholar) and a B.A. from Barnard College (summa cum laude) and is admitted to practice law in New York.

Andrew J. Muratore is published by Pfizer Ventures as Vice President & Chief Counsel, M&A and Licensing. Andrew J. Muratore is Vice President and Chief Counsel, M&A and Licensing at Pfizer. Since joining Pfizer in 2008, Andrew has served as lead counsel to Pfizer Ventures and in that role provides transactional and business counselling in support of all aspects of Pfizer’s equity investing activity. Andrew has advised on the evaluation, structuring and execution of numerous public and private equity and debt financings and exit transactions. Andrew also advises the Pfizer Ventures team on securities, compliance, governance and general legal matters. Andrew is Pfizer Venture’s designated board observer to Prescriber Point, Inc. and has previously served on the boards of Neuronetics (NASDAQ: STIM) and G-Con Manufacturing. In addition to support for Pfizer Ventures, Andrew has led many of Pfizer's most significant M&A efforts, including the acquisitions of Metsera, Global Blood Therapeutics, Biohaven, Trillium, Medivation and Hospira, as well as the combination of Pfizer’s consumer healthcare business with GSK’s to create Haleon PLC, the initial public offering and subsequent split-off of Zoetis, Pfizer’s Animal Health business, and the sale of Capsugel to KKR. Andrew joined Pfizer in 2008 from Covington & Burling LLP. He holds a J.D. from New York University (magna cum laude, Order of the Coif) and a B.A. from Colgate University (magna cum laude). Andrew is admitted to practice law in New York.

Cristian Simms is published by Pfizer Ventures as Breakthrough Fellow WWBD, Associate Pfizer Ventures. Cristian Simms is a member of the Pfizer Breakthrough Fellowship Program and currently serves as a Business Development Associate at Pfizer Ventures. He works closely with the Pfizer Ventures team to assess investment opportunities in innovative biotechnology companies and emerging healthcare technologies, while also supporting portfolio management activities across the firm's investment portfolio. Prior to joining Pfizer, Cristian was a Health Policy Fellow at the League of United Latin American Citizens (LULAC). During his fellowship, he authored policy briefs and analyses covering pharmacy benefit manager (PBM) transparency reform, CMS Innovation Center models, 340B reform, and pharmaceutical supply chain legislation. Cristian earned his B.A. from Howard University.

PorTal Access, Inc. develops and commercialises implantable vascular-access devices for chemotherapy and other long-term infusion therapies. Its FLEXI-PORT system combines a flexible silicone housing, directional stabilisation wings and an integrated forceps-engagement tab to support placement through a small incision with limited dissection. The power-injectable port is offered in 5Fr and 6Fr configurations for arm or chest placement and supports repeated vascular access for medication, fluids, nutrition, blood sampling and contrast injection. The FDA issued a Class II 510(k) substantial-equivalence clearance for FLEXI-PORT on June 17, 2026; its current website says the device is available in the United States. Kidron Capital backs the company and describes its relevance to the vascular-access needs of women receiving chemotherapy. The device company is distinct from Portal Biotech, Portal Space Systems and generic Portal software companies.

Angela Dotson leads operations and business development for PorTal Access. Her responsibilities in the issuer’s June 2026 announcement include the commercial strategy, provider and health-system engagement, distributors and strategic partners following FLEXI-PORT clearance. Earlier releases name her Executive Vice President of Business Development and Head of U.S. Operations.

David Snow joined PorTal Access’s board in February 2026 after four decades of pharmaceutical and biotechnology commercial leadership. He led Regeneron’s commercial immunology team until retirement in 2025 and previously served as President of AstraZeneca China. He holds a business-administration degree from Auburn University and an MBA from NYU Stern.

Hila Ravid is identified as PorTal Access’s Vice President of Quality Assurance and Regulatory Affairs in the FDA’s June 2026 FLEXI-PORT clearance letter. She is the named company contact for the K260916 vascular-access port submission.

Michael Tal founded PorTal Access and leads its development and commercialisation of implantable vascular-access technology. In the issuer’s June 2026 announcement he describes the company’s goal of improving chemotherapy port placement for patients and clinicians.

Avestria Ventures is an early-stage venture-capital firm based in the San Francisco Bay Area that invests in women’s health and female-led life-science businesses. It considers women’s health to include conditions that affect women exclusively, differently or disproportionately, ranging from reproductive health and menopause to cardiovascular disease and Alzheimer’s disease. The firm seeks evidence-based products and services that use technology or data to improve healthcare quality, access and costs, with attention to clinical adoption, reimbursement and scalable commercialization. Its portfolio spans medical devices, diagnostics, therapeutics and digital health. Linda Greub and Corinne Nevinny launched Avestria in2019; the current operating team includes managing partner Linda Greub and partner Tracy Dooley, alongside marketing, legal and social-media professionals, external advisers and separate limited-partner advisory committees.

Andrew J. Perlman, published as Andy Perlman in Avestria’s adviser directory, is a physician-scientist with drug-development experience. His biography identifies co-founding work at AI drug-discovery company X-37 and Velocity Pharmaceutical Development, and earlier roles at Tularik, Genentech, Innate Immune and Affymax. He studied physics at MIT and medicine and science at NYU.

Bart Epker serves on Avestria’s limited-partner advisory committees for Funds I and II. His published background includes founding-partner and healthcare investment work at PAR Capital Management and earlier experience at TA Associates.

Bess Weatherman serves on Avestria’s Fund I limited-partner advisory committee. Her published career includes healthcare investing at Warburg Pincus, leadership of its healthcare group and numerous medical-company directorships. She studied at Mount Holyoke and Stanford Graduate School of Business.

Chimene Linette Liburd, listed in Avestria’s directory as Chimene Liburd, is a physician executive and adviser. Her published background includes primary care, clinical operations, Medicare and Medicaid health plans, and medical training at the University of Maryland.

Corinne Nevinny co-founded Avestria with Linda Greub in 2019 and is listed in its current adviser directory. Her published career includes healthcare investment banking and executive finance and operations roles at Tularik and Edwards Lifesciences. She studied engineering at Stanford and business at Harvard.

Elisa Zhang is a scientific adviser to Avestria with molecular and cellular biology expertise. Her published research focuses on placental development and disease; she studied at Harvard, completed doctoral work at UC Berkeley and subsequently researched at Stanford.

Jennifer Koski is an Avestria adviser whose published background includes finance research and teaching at the University of Washington’s Foster School of Business. She earned degrees at Brown, Harvard Business School and Stanford.

Julia Helvey directs social media at Avestria. Her published biography describes biology training at Brigham Young University and experience in the University of Utah hospital’s labor and delivery unit.

Karen Richards is an Avestria adviser specializing in diagnostic regulation, quality systems, clinical trials and compliance. Her published career includes in-vitro diagnostics and quality work at Precision for Medicine and regulatory submissions in multiple jurisdictions.

Karol Watson is an Avestria adviser and cardiologist whose published biography describes UCLA academic work and leadership of its Barbra Streisand Women’s Heart Health Program. Her research spans cardiovascular prevention, hypertension and women’s heart health.

Linda Greub co-founded Avestria and leads the firm as managing partner. Her published career spans healthcare investment research, equity management and corporate development at Applied Biosystems and other life-science companies. She studied at Yale and Harvard Business School and holds the CFA designation.

Lisa Gaudio directs marketing at Avestria. She has marketing experience across consumer-product categories, studied accounting at the University of Scranton and attended Harvard Business School. Her work communicates developments in women’s health and the firm’s portfolio.

Margot Shapiro is an Avestria adviser with private-equity and venture experience. Her published background includes Goldman Sachs, the Wolverine Venture Fund, co-founding LMN Ventures with Linda Greub and Corinne Nevinny, and Spiral Sun Ventures. She studied at Stanford and Harvard Business School.

Michelle Branch is a venture partner and legal counsel at Avestria. Her legal experience includes Wilson Sonsini, a boutique practice advising venture funds and startups, and teaching at New York University Law School. She holds degrees from Stanford and the University of California, Berkeley.

Mindy Goldman is an Avestria adviser with obstetrics and gynecology expertise. Her published biography describes UCSF clinical work addressing gynecologic health for breast-cancer survivors and women at high hereditary cancer risk.

Sharon Fay serves on Avestria’s limited-partner advisory committees for Funds I and II. Her published biography describes a long investment career at AllianceBernstein and international equity portfolio-management experience. She studied at Brown and Harvard Business School.

Susan Knowles advises Avestria with genomic testing and life-science business experience. Her published career includes investment banking, Applied Biosystems, Illumina and genomics services at UCSF Health.

Tracy Dooley is an Avestria partner trained in biomedical engineering at USC and medicine at Stanford. Her published experience includes healthcare M&A, strategy and global operations at Novartis Diagnostics, and digital-health advisory work.

Thomas Bech Hansen is vice director of New Business and Technologies at FORCE Technology. The September11,2026 ministerial announcement appoints him to Innovation Fund Denmark’s board for July1,2027 through June30,2030, succeeding Mette Glavind. This future appointment is not represented as an October2026current directorship. The announcement also records his previous service on the Danish Council for Research and Innovation Policy.

Christian H. M. Ketels is named as a vice chair in Innovation Fund Denmark’s annual report signed March23,2026. He is absent from the institution’s current authoritative Danish board directory. This is a historical published governance affiliation, with no inferred exact departure date or current employee role.

Kustaa Piha is Athensmed’s founder and CEO, a Finnish physician and healthcare entrepreneur with a2014 medical doctorate and master’s qualifications in political science and economics. He co-founded MedGroup in2007, developed multiple healthcare-service businesses and founded Lähilääkärit in2025. His current Athensmed biography emphasizes long-term ownership, health equality and research-based healthcare investment; the firm’s investments are not automatically attributed to him personally.

Sine Reker Hadrup is a professor and section leader in DTU’s Department of Health Technology, where her research group studies T cells and cancer. Innovation Fund Denmark’s March2026annual report names her as a director. She is absent from the current authoritative Danish board roster, so the institution affiliation is retained as explicitly historical; the stale English directory is not evidence of continued membership.

Sonia Singh is Athensmed’s current Investment Manager. Her published biography describes business-development and venture-capital experience, responsibility across investment analysis and portfolio development, and work on governance and the measurement of social impact in healthcare companies. Additional credentials or earlier employers are not asserted where the firm does not publish them.

Athensmed is a first-generation, family-owned Finnish healthcare investment company and family office founded and led by physician-investor Kustaa Piha. The legal entity Athensmed Oy, business ID2602802-8, is registered in Helsinki; Finland’s official PRH/YTJ API confirms the same domain and May31,2014 trade-register entry, distinct from its February3,2014 business-ID issuance and from Greek AthensMed clinic namesakes. It invests in early-stage health technologies and healthcare services, combining financial investment with active ownership, operating support and an emphasis on accessibility, health equality and measurable social impact. Its current published team consists of CEO/founder Kustaa Piha and investment manager Sonia Singh. Portfolio examples include Sooma’s non-invasive brain-stimulation technology, MVision AI radiotherapy-planning software, Klinik’s AI triage, Finnadvance’s biomimetic drug-development models, Biospectal smartphone-based monitoring and Brinter3D bioprinting. The public list also includes healthcare-service holdings and separately identifies realized exits. Athensmed participated in Sooma’s completed EUR1M equity financing announced December18,2019; the separate EUR250K Business Finland grant is not combined into its equity check. No personal investment by Kustaa Piha is inferred from the firm’s institutional participation. No externally raised LP fund, closed fund corpus, manager AUM or individual allocation was verified; the founder’s more-than50 investments includes direct/portfolio-firm activity and is not represented as50 Athensmed cash transactions. Grants, charitable commitments and healthcare claims are distinguished from completed venture financings or independent regulatory findings.

Mette Glavind is director of the Building and Construction division at the Danish Technological Institute. She is a current Innovation Fund Denmark board member and chairs its Programme Oversight committee. The September11,2026 official announcement extends her board appointment through June30,2027; Thomas Bech Hansen is scheduled to succeed her from July1,2027.

Morten Novak Bro is CEO of maritime control-technology company EMRI, whose own corporate history says he took over the role in2023. Innovation Fund Denmark’s current Danish directory publishes him as a board member and member of the Programme Oversight committee. These institution governance roles do not imply personal subscription to its grants.

Peter Holme Jensen founded Aquaporin and previously served as its CEO. Aquaporin’s own2024director nomination records his service as Chief Innovation Officer from January2022 through January2024 and subsequent work as an entrepreneur and professional director. Innovation Fund Denmark’s current Danish directory includes him on the board and Programme Oversight committee; the translated English directory omits his board card.

Jes Broeng is a serial technology entrepreneur, professor and director of DTU Entrepreneurship and DTU Skylab. He holds a DTU PhD and works across photonics, research commercialization, technology transfer, intellectual property and early-stage business development. His DTU profile identifies him as cofounder of Crystal Fibre, Norlase, Bifrost Communications, Aqubiq, OSAA Innovation and OptoCeutics. The September11,2026 ministerial announcement appoints him to Innovation Fund Denmark’s board through June30,2029.

Charlotte Rønhof is a published current board member of Innovation Fund Denmark. The current SEGES Innovation organization page separately identifies her as an external director and supplies her original portrait. These governance roles are distinct from employment on the public funding institution’s staff.

Henrik Østergaard Breitenbauch is a published current board member of Innovation Fund Denmark. The Royal Danish Defence College appointed him dean from March1,2022. His earlier work included directing the Centre for Military Studies at the University of Copenhagen, strategic work for NATO and research in Danish defence and international affairs. He holds a political-science PhD from the University of Copenhagen.

Ingrid Sofie Harbo was appointed to Innovation Fund Denmark’s board in the September11,2026 ministerial announcement, for a term through June30,2029. She co-owns Harbo Enterprises ApS and holds a University of Copenhagen PhD in biostatistics. Her professional experience spans more than30years in life-sciences research and innovation, leadership and digital transformation, including assessment work for Innobooster and the Industrial Researcher programme.

Anders Eldrup chairs Innovation Fund Denmark. He previously served as Permanent Secretary in Denmark’s Ministry of Finance and CEO of DONG Energy. His professional work spans public administration, corporate governance, innovation and the green transition. The institution records his board entry on March7,2022 and current term through June30,2027.

Philipp J. H. Schröder is an economics professor at Aarhus University and director of the FIND Research Centre. His research covers international trade, industrial economics and macroeconomics. Innovation Fund Denmark names him vice chair; the September11,2026 ministerial announcement renewed his appointment through June30,2029, superseding the directory’s older term-end label.

Cher Shen Kiar is a Senior Associate at Inkef, supporting healthcare-investment diligence and portfolio management. His published investor-panel biography describes three years of biomedical R&D and early drug-discovery experience, with an MRes from King’s College London and a BSc from University College London.

Najma Labyad is publicly listed as Inkef’s Financial Director. The manager identifies her finance function and publishes an authentic name-bound portrait. A detailed current primary career biography and exact joining date are not published on its reviewed directory; no broader executive or investment remit is assumed.

Reitze Douma is publicly listed as Inkef’s Chief Finance & Risk Officer. In a personal2023 announcement he described joining Inkef as Managing Partner after fifteen years at APG Asset Management. The dated appointment title is distinguished from the current manager directory’s finance-and-risk title.

Ryan Sarver is publicly listed as an Inkef Partner. His self-published career account describes joining Redpoint in2013 after work on Twitter’s developer platform and later transitioning from Redpoint. The current Inkef affiliation is independently published by the manager; no personal portfolio check is inferred from this role.

Corné Jansen joined Inkef in2015 and helped build its technology portfolio, including GitLab and Remote. Coalition Capital announced him as its General Partner inJune2024. Inkef’s current site still lists him as Partner and its2026 Quantum Motion investment post credits his continuing portfolio work; the profile preserves this published affiliation without guessing whether he remains a full-time Inkef employee.

Frank Lansink is listed as an Inkef Partner and is identified as General Partner in Quantum Motion’s September2026 investor interview. He describes Inkef’s long-term support for silicon-spin quantum computing, starting with its2020 SeriesA and continuing through subsequent rounds. The sourced professional role is distinct from unrelated similarly named businesses.

Thijs Cohen Tervaert is an Inkef Partner who joined the firm in2016, combining medical training with healthcare and technology investment experience. He graduated in medicine from Leiden University, previously worked at Boston Consulting Group and helped establish the Amsterdam Health and Technology Institute. His portfolio board experience includes Scenic Biotech, TargED, iOnctura, ViCentra and Castor.

Anthony Barry is published by Pfizer Ventures as Executive Director, WWBD / Partner. Anthony Barry, PhD, is a Partner at Pfizer Ventures and Executive Director, Worldwide Business Development. In this role, Anthony is responsible for identifying, evaluating, making, and managing equity investments aligned with the future scientific and strategic directions of Pfizer. He manages Pfizer's venture investments in early-stage biotechnology and platform companies, with a particular focus on novel therapeutic modalities, advanced drug delivery systems, and digital health innovations that have the potential to shape the future of healthcare. Anthony brings over 20 years of distinguished experience at Pfizer, where he has successfully led platform technology groups and external R&D innovation initiatives. Prior to joining the Pfizer Ventures team, he served as the Emerging Science Lead for Biotherapeutics, Technologies and Digital, where he scouted and secured strategic external collaborations and early-stage licensing opportunities. Throughout his career, he has been a key driver in identifying and accelerating emerging science to deliver breakthroughs to patients, and has championed the integration of advanced technologies, including artificial intelligence and machine learning (AI/ML), within the therapeutic discovery and pharmaceutical formulation pipeline. Anthony received his Bachelor of Arts (BA) in Chemistry from Carleton College and earned his Doctor of Philosophy (PhD) in Pharmaceutics from the University of Utah.

Irena Melnikova is published by Pfizer Ventures as Executive Director, WWBD / Partner. Irena Melnikova, PhD, is a Partner at Pfizer Ventures and Executive Director, Worldwide Business Development. Irena is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. Currently, she has responsibilities for Pfizer’s investments in Artios Pharma, CellCentric, Crossbow Therapeutics, Enodia Therapeutics, Flare Therapeutics, Levicept, Oblenio Bio and Priovant. Irena also served as Director of Telavant Holdings until its acquisition by Roche for $7.1 billion. Irena is an accomplished biopharma and finance executive with over 20 years of experience in equity financings in both public and private markets, corporate strategy, business development, and operations. Prior to Pfizer Ventures, Irena served as the Chief Financial Officer at Umoja Biopharma where she was a senior member of the executive team responsible for all aspects of financial strategy and operations of the company. Prior to Umoja, Irena served as a Managing Director, Biopharma Investment Banking at Leerink Partners, where she provided critical advice to biopharma companies and their boards on equity financing strategies, completing over 80 transactions raising over $9 billion for clients. Earlier in her career, Irena held leadership positions at Sanofi and TVM Capital; the latter - a global life sciences venture capital firm. Irena brings a strong scientific background and proven capacity to work across a wide range of therapeutic areas and technology platforms. She earned a Ph.D. in Molecular Medicine/Molecular Biology from the University of Texas.

Michael C. Diem is published by Pfizer Ventures as Vice President, WWBD / Senior Managing Partner. Michael C. Diem, MD is the Senior Managing Partner of Pfizer Ventures and Vice President, Worldwide Business Development. Mike is a member of Pfizer’s WWBD Leadership Team where he is responsible for leading Pfizer Ventures and Global Search and Evaluation. Mike has spent the last two decades as an executive and investor in the pharmaceutical and biotech industries. Before joining Pfizer, Mike was the Chief Financial Officer and Chief Business Officer at Century Therapeutics. Prior to joining Century, he was Senior Vice President of Business and Corporate Development at Amicus Therapeutics, and prior to that, he held a similar role at Aevi Genomic Medicine. Earlier, Mike was the Global Head of Corporate Strategy and Corporate Development at AstraZeneca. At GlaxoSmithKline (GSK), he led business development for the company’s rare disease business unit and was also a partner in GSK’s corporate venture firm, SR One. He has served on numerous corporate boards and is currently a director at OTR Therapeutics, Vibrant Therapeutics and FoRx Therapeutics and a board observer at Cour Pharmaceuticals and Carrick Therapeutics. Dr. Diem obtained his MD from the Rutgers-Robert Wood Johnson Medical School, and an MBA from Case Western Reserve University. He completed his medical training at Duke University and is a Kauffman Fellow.

Published name: John Kim. Published company-directory affiliation (function not disclosed) at Overland AI. Existing unrelated same-name identities preserved.

Overland’s company channel announced his international-growth appointment in October2026. Earlier roles included defense sales at SIG SAUER and European and Asian business development at Oshkosh.

Vibeke Schrøder is published by Innovation Fund Denmark as Senior Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Troels Jørgensen is published by Innovation Fund Denmark as Senior Relations Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Troels Brøns Kjems is published by Innovation Fund Denmark as Senior Analytics Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Thomas Nybo Riis is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Søren Asp Mikkelsen is published by Innovation Fund Denmark as VP - Chief Program Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Stine Bach Holm is published by Innovation Fund Denmark as Program Officer, International & Missions (parental leave). This affiliation is listed in the institution’s October2026 public employee directory; the institution explicitly marks the person as on parental leave. the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Sophie Bogø Rahbek Dyrskjøt is published by Innovation Fund Denmark as Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Simone Uhrenholt Kovacevic is published by Innovation Fund Denmark as Student Assistant, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Sheimaa Shahid is published by Innovation Fund Denmark as Finance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Zoo builds CAD software and infrastructure for designing physical products. Zoo Design Studio combines conventional sketch-and-feature modeling, code-based modeling through the open-source KittyCAD Language (KCL), and natural-language design assistance from its Zookeeper AI agent. These interfaces operate on editable, parametric boundary-representation geometry rather than only producing visual meshes, letting engineers refine parts and preserve the design’s parameters and feature tree. Its GPU-based, cloud-hosted geometry engine and developer APIs support modeling, file conversion and AI-assisted design workflows in other applications. Founded and incubated by Embedded Ventures in 2021, the company changed its brand from KittyCAD to Zoo in December 2023; its current terms identify Zoo Corporation, based in Inglewood, California. KittyCAD remains a product and infrastructure name within the same company.

Rikke Dyrberg Georgi is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Raphael Matias Christensen is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Rebecca Stiig Vibæk is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Pia Westergaard is published by Innovation Fund Denmark as Service & Facility Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Patrick Lund-Sørensen is published by Innovation Fund Denmark as Student Assistant, Økonomi. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Nikoline Yuyan Skov Sørensen is published by Innovation Fund Denmark as Student Assistant, Jura & Compliance. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Nikolaj Pallesen is published by Innovation Fund Denmark as Analytics Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Nikolai Karl is published by Innovation Fund Denmark as Finance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Nadia Holdgaard Krog is published by Innovation Fund Denmark as Compliance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Nadia Aron is published by Innovation Fund Denmark as Student Assistant. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Monica Milter Ehlers is published by Innovation Fund Denmark as Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Miranda Elkjær-Christensen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Michael Hougaard Sandgreen is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Mette-Marie Nielsen is published by Innovation Fund Denmark as Intern. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Michael Friis Lindinger is published by Innovation Fund Denmark as VP - Chief Financial Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Mette Toft Bangsø is published by Innovation Fund Denmark as Executive Assistant. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Vast, also known as Vast Space, builds commercial orbital habitats and space infrastructure for human spaceflight, microgravity research and in-space manufacturing. Its Haven-1 single-module station is under construction for a planned 2027 launch; the larger Haven-2 design is intended to support continuous human presence after the International Space Station. The company develops station structures, life support, power, docking and spacecraft systems in-house, using its flown Haven Demo satellite to test technology before deployment. It also offers high-power satellite buses and is developing lunar power, communications and habitat systems. Customers and collaborators include government space agencies, research organisations and commercial mission partners. Its longer-term artificial-gravity habitation and Moon and Mars programmes are development ambitions, rather than operating crewed stations. Founded in 2021 by Jed McCaleb, it is headquartered in Long Beach, California.

Alex Hudson is listed by Vast as Advisor. Engineering experience spans spacecraft, quantum computing and scientific instruments; formerly led SpaceX avionics.

Andrew Feustel is listed by Vast as Lead Astronaut. Former NASA astronaut and astronaut-office leader with missions to the International Space Station and Hubble telescope.

Benjamin Leeds is listed by Vast as Senior Director, Ground Software & Mission Systems. Part of the early Launcher team, responsible for ground software and ground-segment engineering.

Caryn Schenewerk is listed by Vast as Chief Policy Officer. Specialist in commercial space policy, regulation, government affairs and legal compliance.

Clay Mowry is listed by Vast as Advisor. Commercial space experience includes Voyager Space and Blue Origin sales leadership.

Colin Smith is listed by Vast as Senior Vice President, Haven-1 Program. Former SpaceX engineer who worked on Dragon and launch vehicles; a founding Vast team member leading Haven-1 development.

Daniel DeMattia is listed by Vast as Chief Information Officer. Infrastructure and security experience includes SpaceX, Virgin Orbit and Reliable Robotics.

David Goodwin is listed by Vast as General Counsel. Legal experience covers aerospace, manufacturing, government contracts, supply chains and investigations.

Derek Hassmann is listed by Vast as Vice President, Mission Operations. Human-spaceflight operations experience includes NASA, Axiom Space, Collins Aerospace and Bigelow Aerospace.

Eric Massey is listed by Vast as Senior Vice President, Software and Avionics. Software engineering experience includes JPL, SpaceX, Google Search and the Netflix data platform.

Eva Behrend is listed by Vast as Vice President, Communications. Communications experience includes Uber, SpaceX and Chime and work in corporate and public policy communications.

Garrett Reisman is listed by Vast as Astronaut. Former NASA astronaut with two ISS missions, former SpaceX space-operations director and USC astronautical-engineering professor.

Giorgio Saccoccia is listed by Vast as President, Europe. Previously president of the Italian Space Agency and a senior propulsion and aerothermodynamics leader at ESA.

Hans Koenigsmann is listed by Vast as Advisor. Former SpaceX vice president for mission assurance.